Symptoms of delirium between 24 and 48 hoursa · terminally ill adults with delirium
It is very uncertain whether summary of findings: haloperidol changes symptoms of delirium between 24 and 48 hoursa compared with olanzapine (very low certainty).
1 finding from 1 review
Specific behaviour ‐ agitation · terminally ill adults with delirium
The review found no eligible studies for this question.
2 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Adverse events including extrapyramidal effects · terminally ill adults with delirium
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Efficacy: response (categorical) MSRS/YMRS ≥ 50% decrease in score by end of study · acute mania
Lithium probably leads to lower efficacy: response (categorical) MSRS/YMRS ≥ 50% decrease in score… compared with olanzapine (moderate certainty).
1 finding from 1 review
Efficacy: response (continuous) CGI severity score at end of study · acute mania
1 finding from 1 review
Remission · acute mania
Lithium showed no clear difference in efficacy: remission (categorical) YMRS ≤ 12 at end of study compared with olanzapine (low certainty).
1 finding from 1 review
Acceptability: total withdrawals · acute mania
Lithium may leads to higher acceptability: total withdrawals compared with olanzapine (low certainty).
1 finding from 1 review
Adverse events · acute mania
The review found no eligible studies for this question.
1 finding from 1 review
Lithium for acute mania 2019 · Cochrane Headline outcomes only no estimate extracted
Studies not reported
No studies found
Response rate at 3 weeks (primary efficacy outcome) · Adults (aged 18 and over) with acute mania
Valproate showed no clear difference in response rate at endpoint at 3 weeks (primary efficacy outcome) compared with olanzapine (low certainty).
1 finding from 1 review
Number of participants with any adverse event (primary tolerability outcome) · Adults (aged 18 and over) with acute mania
The review found no eligible studies for this question.
1 finding from 1 review
Adverse effects: 1. Sedation · Adults (aged 18 and over) with acute mania
Valproate leads to lower adverse events ‐ Sedation At 3‐12 weeks (secondary tolerability… compared with olanzapine (high certainty).
1 finding from 1 review
Change in symptom severity at 3 weeks (secondary efficacy outcome) · Adults (aged 18 and over) with acute mania
1 finding from 1 review
Dropout · Adults (aged 18 and over) with acute mania
Valproate showed no clear difference in dropout rate ‐ All‐cause At 3‐12 weeks (secondary acceptability… compared with olanzapine (high certainty).
1 finding from 1 review
Tranquillisation or asleep · psychosis‐induced aggression or agitation (rapid tranquillisation)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Repeated need for tranquillisation ‐ not reported · psychosis‐induced aggression or agitation (rapid tranquillisation)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Specific behaviour: Agitation ‐ clinically important change (PANSS ‐EC reduction ≥ 40% from baseline) ‐ up to 2 hours · psychosis‐induced aggression or agitation (rapid tranquillisation)
ARIPIPRAZOLE (IM) may leads to lower specific behaviour: Agitation ‐ clinically important change (PANSS… compared with OTHER ANTIPSYCHOTIC: b. OLANZAPINE (low certainty).
1 finding from 1 review
Global state: CGI‐S change score up to 2 hours · psychosis‐induced aggression or agitation (rapid tranquillisation)
1 finding from 1 review
Adverse effects: one or more adverse effects during 24 hours · psychosis‐induced aggression or agitation (rapid tranquillisation)
It is very uncertain whether ARIPIPRAZOLE (IM) changes adverse effects: one or more adverse effects during 24 hours compared with OTHER ANTIPSYCHOTIC: b. OLANZAPINE (very low certainty).
1 finding from 1 review
Somnolence · psychosis‐induced aggression or agitation (rapid tranquillisation)
ARIPIPRAZOLE (IM) may leads to lower adverse effects: somnolence during 24 hours compared with OTHER ANTIPSYCHOTIC: b. OLANZAPINE (low certainty).
1 finding from 1 review
Economic outcomes · psychosis‐induced aggression or agitation (rapid tranquillisation)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found